Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06135727 · ClinicalTrials.gov registry record
Screening Protocol
A clinical trial, sponsored by Topcon Corporation.
- Terminated
- Registry status
- 26
- Enrollment target
NCT06135727: Clinical Trial study, sponsored by Topcon Corporation.
NCT06135727 is a clinical trial that was terminated before completion, run by Topcon Corporation. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06135727 was terminated before completion, sponsored by Topcon Corporation.
- TERMINATED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The objective of this study is to collect data for the development and validation a screening process using aggregate data. In this study, data collection will encompass both retrospective and prospective approaches across multiple sites in the United States.
Primary Outcome
Using Maestro2 OCT
Interventions
- DEVICE Maestro2 OCT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2024-08-02 |
Why NCT06135727 stopped before completion
NCT06135727 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Maestro2 OCT is the first listed.
NCT06135727 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06135727 about?
NCT06135727 is a clinical study titled "Screening Protocol". The objective of this study is to collect data for the development and validation a screening process using aggregate data. In this study, data collection will encompass both retrospective and prospective approaches across multiple sites in the United States.
What is the current status of trial NCT06135727?
This trial is currently terminated. The enrollment target is 26 participants. The study started on 2023-11-07. Estimated completion is 2024-08-02.
What interventions are being tested in trial NCT06135727?
The interventions under investigation include: Maestro2 OCT (DEVICE).
Who is sponsoring clinical trial NCT06135727?
This trial is sponsored by Topcon Corporation, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI